highly significantp < 0.001
Placental release of 8-Isoprostane is about twice as high in women with GDM compared with women who have healthy pregnancies, with this elevation being highly significant ( p < 0.001).
Placental release of 8-Isoprostane is about twice as high in women with GDM compared with women who have healthy pregnancies, with this elevation being highly significant ( p < 0.001).
Multi-centric randomized trials administering myo-inositol and D-chiro-inositol plus Vitamin D from 12 weeks of gestation demonstrated an improved trend in reducing GDM rates (3.22% in the treatment group versus 5.08% in the vitamin D-alone group), although the difference did not reach statistical significance [ 154 ].